Search This Blog

Showing posts with label hide. Show all posts
Showing posts with label hide. Show all posts

Friday 26 October 2012

Closed drug trials leave patients at risk and doctors in the dark

 

Drug companies can hide information about their drugs from doctors and patients, perfectly legally, with the help of regulators. We need proper legislation

We need muscular legislation to ensure that all information about all trials on all currently used drugs is made available to doctors
We need muscular legislation to ensure that all information about all trials on all currently used drugs is made available to doctors Photo: Alamy

This week, Daily Telegraph readers have been astonished by revelations about the incompetent regulation of implantable medical devices. This paper has clearly demonstrated that patients are put at risk, because of flawed and absent legislation. But many of these issues apply even more widely, to the regulation of all medicines, and at the core is a scandal that has been shamefully ignored by politicians.
 
The story is simple: drug companies can hide information about their drugs from doctors and patients, perfectly legally, with the help of regulators. While industry and politicians deny the existence of this problem, it is widely recognised within medical academia, and meticulously well-documented. The current best estimate is that half of all drug trials never get published.
 
The Government has spent an estimated £500 million stockpiling Tamiflu to help prevent pneumonia and death in case of an avian flu epidemic. But the manufacturer, Roche, continues to withhold vitally important information on trials of this drug from the universally respected Cochrane Library, which produces gold-standard summaries on medicines for doctors and patients. Nobody in the Department of Health or any regulator has raised a whisper about this, though Roche says it has made “full clinical study data available to health authorities around the world”.
 
In fact, while regulators should be helping to inform doctors, and protect patients, in reality they have conspired with companies to withhold information about trials. The European Medicines Agency, which now approves drugs for use in Britain, spent more than three years refusing to hand over information to Cochrane on Orlistat and Rimonabant, two widely used weight loss drugs. The agency’s excuses were so poor that the European Ombudsman made a finding of maladministration.
 
Even Nice, the National Institute for Health and Clinical Excellence, plays along with this game. Sometimes chunks of its summary documents on the benefits and risks of drugs are redacted, because data has only been shared by companies under unethical “confidentiality agreements”. The numbers are blacked out in the tables, to prevent doctors seeing the benefits from a drug in each trial; and even the names of the trials are blacked out, as if they were code names for Russian agents during the Cold War.
 
This is a perverse and bizarre situation to have arisen in medicine, where decisions are supposed to be based on evidence, and where lack of transparency can cost lives. Our weak regulations have been ignored, and if we don’t act quickly, the situation will soon get much worse. The European Medicines Agency’s sudden pledges of a new era of transparency are no use: it has a track record of breaking such promises. We need proper legislation, but the new Clinical Trials Directive, currently passing through the European Parliament, does nothing to improve things.

Are you glazing over at the mention of European directives? This is where it all went wrong. Sunlight is the best disinfectant, but these issues have been protected from public scrutiny by a wall of red tape, while the people we trust to manage these complex problems have failed us. Regulators have lacked ambition. Politicians have ignored the issue. Journalists have been scared off by lobbyists. Worst of all, the doctors in medical membership bodies, the Royal Colleges and the Societies, even the patient groups – many of them funded by industry – have let us all down.

This must change. We need muscular legislation to ensure that all information about all trials on all currently used drugs is made available to doctors. We need the members of patient groups and medical bodies to force their leaders to act. And we need EU medicines regulators to be held to public account, for the harm they have inflicted on us.

Ben Goldacre is a doctor and author of 'Bad Pharma’ (4th Estate 2012)